Medicenna to Present at Investor and Scientific Conferences in September
TORONTO and HOUSTON,
An on-demand corporate presentation will be available here and on the “Investor Relations” section of Medicenna's website beginning at
The Promise of
An overview of previously announced data from Medicenna’s IL-2 programs will be featured in an oral presentation titled, “IL-2 Superkines Engineered with Tunable Selectivity for IL2Rα, β and γ Chains Enabling Pro- and Anti-Immune Functions.” The presentation will take place at
The conference is taking place at the
Cytokines 2022: 10th Annual Meeting of the
Findings from Medicenna’s preclinical Superkine programs will be featured in the following two poster presentations:
- A Next Generation Bifunctional Superkine for Immunotherapy (BiSKIT™) Encompassing the Combined Therapeutic Potency of IL-2 Super-Agonist and Anti-PD1
- Fc-MDNA413 is a Novel Long-Acting IL-4/IL-13 Super-Antagonist that
Suppresses M2a TAM Skewing and In Vivo Tumor Growth Including Synergy with an IL-2 Super-Agonist.
The conference is taking place both virtually and in-person at the
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
For further information please contact:
Investor Contact
For more investor information, please contact:
Source: Medicenna Therapeutics Corp.